MORIN-HEIGHTS, QC, Jan. 10, 2017 /CNW Telbec/ - Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a Patent License Agreement with nSequence Center for Advanced Dentistry and National Dentex Corporation (each, a "Licensee"). As part of the agreement, Sinlab granted Licensees a non-exclusive worldwide license to make, use, sell and offer to sell inventions covered by its patents, including patents relating to its Technobar and Technoguide technologies, under terms undisclosed for confidentiality reasons.
Unlicensed entities should obtain an appropriate license from Sinlab by contacting M. Jean Kingsley at [email protected].
The Company previously announced settlement and/or license agreements that include Biomet 3i, LLC (formerly Implant Innovations, Inc.); Delcam USA, Inc. and Delcam Holdings, Inc.; Cagenix, Inc.; Dentsply International Inc.; Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc.; Biocad Médical Inc.; Nobel Biocare USA, LLC; Nobel Biocare Procera, LLC; 3Shape A/S, exocad America, Inc., MIS Implants Technologies, Ltd., SICAT Gmbh & Co. KG and James R. Glidewell Dental Ceramics, Inc. The Company is currently pursuing its licensing program with other industry participants. The Company cannot predict the outcome of its ongoing negotiations or of any legal proceedings it may decide to institute against those entities that fail or refuse to contract a license. The decision to take legal proceedings will be based on available information and the Company's assessment of all relevant facts and circumstances, including costs involved with such proceedings. Such costs are unpredictable and may be substantial.
Caution regarding forward-looking statements
This news release contains certain forward-looking statements regarding the Company's expectation of future events, including potential claims and the institution of legal proceedings. Such expectations are based on certain assumptions based on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could lead actual results to differ include, amongst others, factors that may impact claims and legal proceedings, such as interpretation of factual matters, time and money involved in undertaking legal proceedings, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.
About Pro-Égaux Inc.
Pro-Égaux through its wholly owned subsidiary, Technique d'usinage Sinlab Inc., is a company based in Lachenaie, Quebec, specializing mainly in the conception and design of titanium products to be used in the dental prosthesis restoration industry.
Neither NEX, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of NEX and the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Capital Pro-Egaux Inc.
For further information: For further information about this Press Release: Capital Pro-Égaux Inc., Pierre Désormeau, President, Tel.: (514) 616-0612, Fax: (450) 226-1923, [email protected]